Colorectal Adenocarcinoma Clinical Trial
Official title:
Expanded Cohort of Patients With Refractory Metastatic Colorectal Cancer (MCRC) Treated With Bevacizumab and Everolimus
The purpose of this study is to find the safest and most effective dose of the drugs
bevacizumab and everolimus given in combination for the treatment of metastatic colorectal
cancer. Bevacizumab (also called Avastin™) is a drug that is given intravenously (through a
vein). Everolimus (also called RAD001) is a tablet that is taken by mouth.
Bevacizumab is a protein that is thought to prevent the formation of blood vessels tumors
need to grow. RAD001 has multiple capabilities, like bevacizumab it may prevent the
formation of blood vessels needed by tumors and it also may stop tumor growth.
This study will try to find the safest dose of these drugs that can be tolerated when taken
in combination. The study will look at how the drugs work in the body, and will see if there
is any effect on metastatic colorectal cancer.
This open-label, non-randomized expanded cohort trial of bevacizumab and RAD001 for patients
with refractory metastatic colorectal cancer is designed to assess preliminary efficacy as
well as the safety and tolerability of this combination. Patients will be accrued to this
study at Duke University Medical Center and The Duke Oncology Outreach Network (DON)
After satisfying eligibility and screening criteria, patients will be treated on 28 day
cycles.
- The treatment regimen is as follows:
10 mg/kg Bevacizumab intravenous on days 1 and 15 and 10mg everolimus (RAD001) daily by
mouth
- Toxicity will be assessed every visit, and as clinically indicated.
- Efficacy will be assessed every 2 cycles, and as clinically indicated.
- Patients may remain on treatment as long as they are deemed to be clinically benefiting
from treatment, do not have progressive disease on restaging imaging (Section 6.0), or
do not have any other reason for discontinuation of treatment as outlined in Section
3.4.
- Patients will undergo correlative studies as outlined in the study protocol
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04094688 -
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06050447 -
Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
|
||
Recruiting |
NCT05504252 -
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
|
Phase 2 | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05902988 -
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT05477836 -
Feasibility and Safety of MiWEndo-assisted Colonoscopy
|
N/A | |
Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03715933 -
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
Phase 1 | |
Recruiting |
NCT04870879 -
Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors
|
N/A | |
Recruiting |
NCT04773769 -
Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas
|
N/A | |
Recruiting |
NCT04739072 -
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
|
||
Recruiting |
NCT06134440 -
ImmunoNutrition and Colorectal Adenocarcinoma Surgery - INCAS Study
|
N/A | |
Withdrawn |
NCT03708536 -
Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma
|
Phase 3 | |
Withdrawn |
NCT02413853 -
Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00165217 -
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04457284 -
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
|
Phase 2 | |
Suspended |
NCT04111172 -
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT06118658 -
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
|
Phase 2 | |
Completed |
NCT00593060 -
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
|
Phase 1 |